1

New Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation

Dr. Klaus Suwelack Johnson & Johnson Innovation, Janssen-Cilag Germany, Neuss

May 11th , 2015

2

• One of the LEADING health care companies

• Eighth largest pharmaceutical company

• Sixth largest Biotech company

• More than 250 operating companies in 60 countries

• Products are offered in 175 countries

• More than 129.000 employees

MEDICAL DEVICES & DIAGNOSTICS

CONSUMER

PHARMACEUTICALS

Revenue 2013: 71,3 bn $ U.S.

Johnson & Johnson: A leading global health care company.

3

Janssen Company Profile

Who We Are

Last updated: March 2015

One of the LEADING PHARMACEUTICAL RESEARCH COMPANIES

Founded in 1953 in GERMANY since 1959 PART OF JOHNSON & JOHNSON since 1961 years

62 Employees around the world: Approx. 40,000 Approx. 800 in Germany

2014 sales: Approx. EUR 26.6 BIL.

EUR1.04 BIL. in GERMANY

Key therapeutic areas: INFECTIOUS DISEASES IMMUNOLOGY ONCOLOGY NEUROLOGY/PSYCHIATRY

4 ACTIVE COMPOUNDS on the WHO LIST OF ESSENTIAL MEDICINES

6

research and development centers, 8 Production sites IN EUROPE 10

Active on

5 continents

4

Janssen Company Profile

Our Key Therapeutic Areas

Neurology Psychiatry Oncology Immunology Infectious

Diseases

ADHD

Dementia

Epilepsy

Schizophrenia

Pain

Anemia in cancer patients

Multiple myeloma Prostate cancer Breast cancer Ovarian cancer

Acute myeloid leukemia Castleman disease Chronic lymphoid

leukemia Mantle cell lymphoma

Asthma

Psoriasis

Psoriatic arthritis

Hepatitis C

HIV/AIDS

Tuberculosis

5

Our Identity

In the Tradition of Our Founder

“Time is precious, we are running out of it, and the patients are waiting.” Dr. Paul Janssen (1926 – 2003)

2002 2012 2002 2012

16%

33%

20%

50%

Top 10 Pharmaceutical

companies Source: Medtrack; Johnson & Johnson The Wall Street Journal

External Innovation Percentage of drugs under development that were initially developed at another company

• Medical need and differentiation

• Deep scientific and medical expertise

• Select the best science – internal and external

• Excellence in global execution

• Speed to market

Our R&D Strategy: Focus on Transformational Innovation that Solves Unmet Medical Need

Our Approach to Sourcing Innovation

8

Early Exploration

Discovery Concept

Early Development

Late

Development Regulatory Post Launch

Appr

oval

Innovation Centres Business Development

Johnson & Johnson Development Corporation

Internal Discovery &

Early Research

Biomarkers, Research

Capabilities Global

Development

We Find the Best Science "The world is our lab"

9

Licensing & Acquisitions

External Collaborations • Academia • Biotech • Pharma • Consortia

Internal Research

Innovation Center Satellite

Boston

San Diego

California London

Israel

Russia

Australia

Shanghai

Singapore

Japan

Innovation is everywhere, but mostly outside of our own organization

11

Extending Network through Local Scouts

Innovation Centers:

• Local Scouts reach out to extend coverage in several European countries

• Scanning for opportunities and liaising with biotech & academia and maintaining interactions with partner organizations

(Israel)

(Moscow)

Our Janssen Pharmaceutical business is one of the most productive and innovative in the world. In the past 10 years, we have brought more differentiated pharmaceutical products to patients than any other company. The teams at the Johnson & Johnson Innovation Centers are interested in exploring early stage therapeutic and vaccine technologies up to clinical proof of concept in the following areas:

Pharmaceuticals

12

Cardiovascular and Metabolism • Type 2 Diabetes • Heart Failure

Immunology • Rheumatoid

Arthritis • Inflammatory

Bowel Disease • Psoriasis • Pulmonary

Infectious Diseases and Vaccines • Hepatitis • Respiratory

Infections

Neuroscience • Mood Disorders • Alzheimer’s

Disease • Pain

Oncology • Prostate Cancer • Lung Cancer • Hematologic

Malignancies • Colorectal Cancer

What We Consider & How We Prioritize

13

• Conviction level of experts in science & target • Ability to establish pre-clinical and clinical POC • Time and cost to preclinical and clinical POC • Leadership potential (competitive landscape) • Strategic fit for J&J • IP strength • Collaboration capability of partner • Patient impact (medical need) • Societal impact (e.g. patient years) • Transformative potential at time of launch • Cost of access (deal terms)

Delivering Clinical

POC products

POC Proof of Concept

Co-creation Model

14

Innovator Product Idea

Investment

Expertise

Faci

litie

s (L

abs,

offi

ces)

R

&D

ca

pabi

litie

s

J&J Innovation

Centers providing

access to..

Advancing innovative products by enabling access to a full range of incubation ‘ingredients’

supplied by network of strategic partners

Products for

Patients

Right Opportunity

– Ideas / Concepts – Scientific Methods – Technologies +

Tools – Diagnostics – Pharmaceuticals – Consumer Products – Medical Devices

Partnership Model: Flexible and Custom

From

transformational ideas through clinical proof of concept

Right Solution

– Janssen Labs or Janssen Labs@

– Advice + Mentorship – Partnering Offices: J&J

Innovation@ – J&J Innovator & EIR Program – Incubation & Seed Financing – Venture Financing – Investment Partners – Strategic LP Relationships – R&D Collaborations – Soft and Call Options – Licensing – Acquisition

Strategically aligned J&J Innovation areas of focus

Catalyzing innovation at Johnson & Johnson is about creating strong networks of people who can combine resources, ideas and technologies in a new way.”

“

Paul Stoffels, MD Chief Scientific Officer

17

Thank you – Questions? Dr. Klaus Suwelack +49 172 413 670 2 ksuwelac@its.jnj.com www.jnjinnovation.com